Skip navigation
Centers for Disease Control and Prevention
 CDC Home Search Health Topics A-Z
Prevention Among Injection Drug Users

 IDU HIV Prevention
 IDU Home
General Information
 Fact Sheet Series:
 Syringe Disinfection for Injection Drug Users
 Viral Hepatitis
 Substance Abuse
Treatment
 Criminal Justice
 Access to Sterile Syringes
Comprehensive
Approach Brochure
Comprehensive
Approach Document
 Dear Colleague Letters
Explore IDU Topics
Other Publications
 Order Printed Materials
Comments
   

U.S. Department of Health and Human Services

Letters about Injection Drug Users and HIV Prevention Issues

Logos: CDC, HRSA, NIDA, SAMHSA

May 9, 1997

HIV Prevention Bulletin: Medical Advice for Persons who Inject Illicit Drugs

Dear Colleague:

Preventing drug use and providing substance abuse treatment for persons who inject illicit drugs are crucial to preventing many blood-borne infections, including human immunodeficiency virus (HIV). However, many drug users are not currently in substance abuse treatment programs because of multiple factors including the limited availability of these programs and the lack of readiness or willingness of some drug users to enter substance abuse treatment. Consequently, substantial numbers of drug users continue to inject drugs.

This bulletin summarizes new information on preventing transmission of HIV and other blood-borne infections among persons who inject drugs and updates prevention recommendations published in April 1993.*1 The findings of a 1995 workshop on the use of sterile syringes by persons who inject drugs and several recent publications2,3,4,5,6 indicate that persons who inject drugs should use sterile syringes** to prevent the transmission of HIV and other blood-borne infectious diseases. These conclusions should be considered by clinicians providing health care to persons who use or inject drugs and by public health professionals planning and carrying out HIV prevention programs for injection drug users (IDUs). Health professionals should inform IDUs that using sterile syringes is safer than reusing syringes, including syringes that have been disinfected with bleach. The information in this bulletin has been prepared for health professionals involved in programs serving persons who inject drugs. Separate educational materials will be prepared to inform drug injectors of these findings.

*Issued jointly by the Centers for Disease Control and Prevention, the National Institute on Drug Abuse of the National Institutes of Health, and the Center for Substance Abuse Treatment of the Substance Abuse and Mental Health Services Administration.

**The term "syringes" is used throughout this bulletin to refer to both syringes and needles.


INJECTION DRUG USE AND THE TRANSMISSION OF HIV AND OTHER BLOOD-BORNE INFECTIONS

The reuse and "sharing" of blood-contaminated injection equipment and blood-contaminated dissolved drugs play substantial roles in the transmission of HIV,2 hepatitis B virus (HBV), hepatitis C virus (HCV),7 and other blood-borne infections. These infections cause illness and death among drug users, their sex partners, and, through mother-to-infant transmission, their children. More than one third (35%) of all AIDS cases reported in the United States in 1995 were directly or indirectly associated with injection drug use.8

Blood is introduced into needles and syringes at the start of every intravenous injection. The reuse of a blood-contaminated syringe by another drug injector (sometimes called "direct syringe sharing") carries a substantial risk of transmission of blood-borne infections, including HIV, HBV, and HCV. In addition, blood and blood-borne infections can be introduced into drug solutions by the use of blood-contaminated syringes to prepare drugs; the reuse of water; the reuse of bottle caps, spoons, or other containers ("spoons" and "cookers") used to dissolve drugs in water and to heat drug solutions; and the reuse of small pieces of cotton or cigarette filters ("cottons") used to filter out particles that could block the needle.9,10 Multiperson use of contaminated water, dissolved drugs, and drug preparation equipment is sometimes called "indirect sharing." 11

Because some "street" sellers of syringes repackage used syringes and sell them as sterile syringes,12 persons who continue to inject drugs should obtain syringes from reliable sources of sterile syringes, such as pharmacies.

In addition to HIV, HBV, HCV and other blood-borne infections, persons who inject drugs are at risk of other serious infections.13 Use of alcohol swabs to clean the injection site prior to injection has been shown to reduce the occurrence of cellulitis, injection site abscesses, and, possibly, endocarditis among persons who inject drugs.13, 14


CRITICAL IMPORTANCE OF PREVENTION AND TREATMENT OF DRUG DEPENDENCE

The risks of transmission of blood-borne illnesses are compelling reasons for strengthening public health and community efforts to help persons avoid starting drug injection and to help IDUs stop using drugs. Addiction is a major factor in the use of drugs such as heroin, cocaine, and amphetamines. While the recommendations in this bulletin will help reduce the individual and public health risks associated with injection drug use, the ultimate goals are to prevent at-risk individuals from initiating injection drug use and to help drug injectors stop drug injection through substance abuse treatment and recovery from addiction. For most persons who are addicted to drugs, admission to drug and alcohol treatment programs is a key step in reducing and/or stopping their drug use.


A 1995 WORKSHOP AND RECENTLY PUBLISHED STUDIES AND RECOMMENDATIONS

On February 15-16, 1995, a workshop on the role of sterile syringes in the prevention of HIV transmission among drug users who continue to inject was held at Johns Hopkins University in Baltimore, Maryland. The workshop was sponsored by the Centers for Disease Control and Prevention (CDC), the Center for Substance Abuse Treatment (CSAT) of the Substance Abuse and Mental Health Services Administration (SAMHSA), the National Institute on Drug Abuse (NIDA) of the National Institutes of Health (NIH), and the Johns Hopkins University School of Hygiene and Public Health.

In September 1995, the findings and conclusions of a two-year National Academy of Sciences (NAS) study were published in a report entitled "Preventing HIV Transmission: The Role of Sterile Needles and Bleach."2 Also in September 1995, the Journal of Acquired Immune Deficiency Syndrome and Human Retrovirology published reports of the evaluation of laws enacted in Connecticut in 1992 that allowed the purchase without a prescription and the legal possession of as many as 10 syringes.3,4

In 1996, the U.S. Preventive Services Task Force published guidelines recommending that drug users who continue to inject be advised to use sterile syringes and take other steps to prevent health problems associated with injecting drugs.5 Also in 1996, the American Medical Association published a physician guide to HIV prevention that stated that primary care physicians can help their patients reduce HIV risk from injecting drugs by encouraging them to "Use a new needle and syringe each time drugs are injected."6

Based on discussions during the 1995 Johns Hopkins workshop and the findings from these studies, the new recommendations for drug users who continue to inject drugs include: (1) substance abuse treatment to reduce or eliminate drug injection; (2) the use of sterile syringes to reduce the spread of blood-borne infections; (3) the use of new, ideally, sterile water and equipment to prepare drugs; and (4) adequate disinfection of the injection site by drug users to prevent local infection and endocarditis.


IMPLICATIONS OF NEW INFORMATION ON HIV RISKS ASSOCIATED WITH DRUG INJECTION

To minimize the risk of disease transmission, persons who continue to inject drugs should be advised to always use sterile injection equipment; warned never to reuse needles, syringes, and other injection equipment; and told that using syringes that have been cleaned with bleach or other disinfectant is not as safe as using new, sterile syringes. The NAS report stated: "For injection drug users who cannot or will not stop injecting drugs, the once-only use of sterile needles and syringes remains the safest, most effective approach for limiting HIV transmission."2 CDC recommends that all syringes used for parenteral injections be sterile.15 Drug preparation equipment, such as "cottons," "cookers," water, and syringes should not be reused because they are usually contaminated with blood. Most syringes and needles used by drug injectors were not designed for reuse. Boiling needles and syringes for 15 minutes between uses can disinfect the equipment. However, boiling may alter the shape and functioning of the plastic syringes widely used by drug injectors in the United States. Disinfecting previously used needles and syringes with bleach (or other chemicals) can reduce the risk of HIV transmission, but using disinfected syringes is not as safe as using a new, sterile needle and syringe.16 The NAS report found that bleach disinfection (using the procedures described in the April 1993 NIDA, CSAT, CDC bulletin on bleach) is likely to be effective but ". . . is clearly an intervention to be used when injection drug users have no safer alternatives."2


PROVISIONAL RECOMMENDATIONS TO DRUG USERS WHO CONTINUE TO INJECT

Health care workers involved in programs that serve drug users should communicate the following recommendations to drug users who continue to inject. Adhering to these drug preparation and injection procedures will reduce the public health and individual health risks associated with drug injection for both drug users and other persons in their communities.

Persons who inject drugs should be regularly counseled to:

I. Stop using and injecting drugs.

II. Enter and complete substance abuse treatment, including relapse prevention.

III. Take the following steps to reduce personal and public health risks, if they continue to inject drugs:

  • Never reuse or "share" syringes, water, or drug preparation equipment.
  • Use only syringes obtained from a reliable source (e.g., pharmacies).
  • Use a new, sterile syringe to prepare and inject drugs.
  • If possible, use sterile water to prepare drugs; otherwise use clean water from a reliable source (such as fresh tap water).
  • Use a new or disinfected container ("cooker") and a new filter ("cotton") to prepare drugs.
  • Clean the injection site prior to injection with a new alcohol swab.
  • Safely dispose of syringes after one use.

The availability of new, sterile syringes varies, depending on state and local regulations regarding the sale and possession of syringes and on other factors, such as the existence of syringe exchange programs sponsored by local HIV prevention organizations.17 If new, sterile syringes and other drug preparation and injection equipment are not available, then previously used equipment should be boiled or disinfected with bleach using the methods recommended in the April 1993 bulletin.1

In addition, drug users should be provided information on how to prevent HIV transmission through sexual contact and, for women, information on reducing the risk of mother-to-infant HIV transmission.


FOR MORE INFORMATION

For more information or to comment on this bulletin, please contact the following staff members of the organizations releasing this bulletin:
CDC - Dr. T. Stephen Jones at 404-639-5200 (fax 404-639-5260);
HRSA - Dr. A. Russell Gerber at 301-443-4588 (fax 301-443-1551);
NIDA - Dr. Steven W. Gust at 301-443-6480 (fax 301-443-9582); and
SAMHSA - Mr. Adolfo Mata at 301-443-5305 (fax 301-443-3817).

Sincerely yours,

Signature: Helene D. Gayle, M.D., M.P.H.
Helene D. Gayle, M.D., M.P.H.
Director
National Center for HIV, STD and TB Prevention
Centers for Disease Control and Prevention

Signature: Joseph F. OÍNeill, M.D., M.P.H.
Joseph F. O’Neill, M.D., M.P.H.
Associate Administrator for AIDS Health Resources and Services
Administration

Signature: Steven W. Gust, Ph.D.
Steven W. Gust, Ph.D.
Acting Director, Office on AIDS
National Institute on Drug Abuse
National Institutes of Health

Signature: Adolfo Mata
Adolfo Mata
Associate Administrator for AIDS (Acting)
Substance Abuse and Mental Health Services Administration

 


REFERENCES:

Single copies of the publications marked with ** and the executive summary of the National Academy of Sciences report are available at no cost from the CDC National AIDS Clearinghouse (1-800-458-5231).

  1. CDC, CSAT NIDA Prevention Bulletin April, 1993.**
  2. Normand J, Vlahov D, Moses LE, eds. Preventing HIV transmission: the role of sterile needles and bleach. Washington, DC: National Academy Press, 1995.
  3. Valleroy LA, Weinstein B, Jones TS, et al. Impact of increased legal access to needles and syringes on community pharmacies' needle and syringe sales—Connecticut, 1992-1993. J Acquir Immune Defic Syndr Hum Retrovirol 1995;10:73-81.**
  4. Groseclose SL, Weinstein B, Jones TS, et al. Impact of increased legal access to needles and syringes on the practices of injecting-drug users and police officers—Connecticut, 1992-93. J Acquir Immune Defic Syndr Hum Retrovirol 1995;10:82-9.**
  5. U.S. Preventive Services Task Force. Guide to clinical preventive services (2nd ed.). Baltimore: Williams & Wilkins, 1996.
  6. American Medical Association. A physician guide to HIV prevention. Chicago, Illinois: American Medical Association, 1996.
  7. Alter M. Epidemiology of hepatitis C in the West. Sem Liver Dis 1995;15:5-14.
  8. CDC. AIDS associated with injecting-drug use—United States, 1995. MMWR 1996;45:392-8.**
  9. Koester SK, Booth R, Weibel W. The risk of HIV transmission from sharing water, drug mixing containers, and cotton filters among intravenous drug users. Int J Drug Policy 1990;1:28-30.
  10. Jose B, Friedman SR, Curtis R, et al. Syringe-mediated drug-sharing (backloading): a new risk factor for HIV among injecting drug users. J Acquir Immune Defic Syndr 1993;7:1653-60.
  11. Koester SK, Hoffer L. "Indirect sharing": additional HIV risks associated with drug injection. AIDS & Public Policy Journal 1994;9:100-105.
  12. Des Jarlais DC, Friedman SR, Hopkins W. Risk reduction for the acquired immunodeficiency syndrome among intravenous drug users. Ann Intern Med. 1985;103:755-9.
  13. Spijkerman IJB, Vanameijden EJC, Mientjes GHC, Coutinho RA, Vandenhoek A. Human immunodeficiency virus infection and other risk factors for skin abscesses and endocarditis among injection drug users. J Clin Epidemiol.1996;49:1149-1154
  14. Vlahov D, Sullivan M, Astemborski J, Nelson KE. Bacterial infections and skin cleaning prior to injection among intravenous drug users. Public Health Rep 1992;107:595-8.
  15. CDC. Improper infection-control practices during employee vaccination programs—District of Columbia and Pennsylvania, 1993. MMWR 1993;42:969-71.
  16. Haverkos HW, Jones TS. HIV, drug-use paraphernalia, and bleach. J Acquir Immune Defic Syndr 1994;7:741-2.**
  17. Gostin LO, Lazzarini Z, Jones TS, Flaherty K. Prevention of HIV/AIDS and other blood-borne diseases among injection drug users: A national survey on the regulation of syringes and needles. JAMA 1997:277:53-62.**
 designed by mike oppenheimer  
   
Go to top
Last Updated: October 3, 2002

Centers for Disease Control & Prevention
National Center for HIV, STD, and TB Prevention
Divisions of HIV/AIDS Prevention

Privacy Policy | Accessibility

FirstGov - The First Click to the U.S. Government